Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Department of Gastroenterology, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan.
J Gastroenterol Hepatol. 2018 Nov;33(11):1889-1896. doi: 10.1111/jgh.14277. Epub 2018 May 29.
An assay for Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA -M2BP) has been reported as a useful non-invasive marker for the evaluation of the staging of fibrosis in several chronic liver diseases. However, available data on the effect of WFA -M2BP level in decompensated cirrhosis patients were limited. It is important that these investigations can validate the diagnostic utility of WFA -M2BP in the full range of patients with liver cirrhosis.
A multicenter study was conducted at five locations in Japan. A total of 207 patients with liver cirrhosis were enrolled in the present study. To determine whether or not the WFA -M2BP value was associated with a progression of fibrosis among cirrhosis, this study examined WFA -M2BP levels between patients with cirrhosis in the decompensated and compensated groups.
The numbers and proportions of compensated and decompensated patients were 113 (54.6%) and 94 (45.4%), respectively. The average WFA -M2BP levels were 2.22 ± 1.61 in the compensated group and 6.91 ± 5.04 in the decompensated group. Significantly higher WFA -M2BP levels were observed in the decompensated group than those in the compensated group (P < 0.0001). The respective cut-off index values for decompensated cirrhosis were estimated using receiver-operating characteristic curves for WFA -M2BP levels. Using a cut-off index value of 3.37 for WFA -M2BP, predicting decompensated cirrhosis had a sensitivity of 77.8% and a specificity of 86.7%.
WFA -M2BP values were higher in patients with decompensated liver cirrhosis.
已有报道称，针对大豆凝集素阳性人 Mac-2 结合蛋白（WFA-M2BP）的检测方法可作为评估多种慢性肝病纤维化分期的一种有用的非侵入性标志物。然而，关于失代偿性肝硬化患者 WFA-M2BP 水平的相关数据有限。重要的是，这些研究可以验证 WFA-M2BP 在所有肝硬化患者中的诊断效用。
本研究在日本的五个地点进行了一项多中心研究。共纳入 207 例肝硬化患者。为了确定 WFA-M2BP 值是否与肝硬化纤维化进展相关，本研究比较了失代偿组和代偿组患者的 WFA-M2BP 水平。
代偿组和失代偿组患者的例数和比例分别为 113 例（54.6%）和 94 例（45.4%）。代偿组的平均 WFA-M2BP 水平为 2.22±1.61，失代偿组为 6.91±5.04。失代偿组的 WFA-M2BP 水平明显高于代偿组（P<0.0001）。使用 WFA-M2BP 水平的受试者工作特征曲线估计了用于诊断失代偿性肝硬化的截断指数值。使用 WFA-M2BP 的截断指数值 3.37 预测失代偿性肝硬化的敏感性为 77.8%，特异性为 86.7%。
失代偿性肝硬化患者的 WFA-M2BP 值较高。
